Coherus Oncology (CHRS) Leases: 2015-2024
Historic Leases for Coherus Oncology (CHRS) over the last 2 years, with Dec 2024 value amounting to $4.5 million.
- Coherus Oncology's Leases fell 23.58% to $4.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 million, marking a year-over-year decrease of 23.58%. This contributed to the annual value of $4.5 million for FY2024, which is 23.58% down from last year.
- Latest data reveals that Coherus Oncology reported Leases of $4.5 million as of Q4 2024, which was down 23.58% from $5.9 million recorded in Q4 2023.
- Coherus Oncology's Leases' 5-year high stood at $11.5 million during Q1 2020, with a 5-year trough of $4.5 million in Q4 2024.
- Its 3-year average for Leases is $5.4 million, with a median of $5.7 million in 2022.
- As far as peak fluctuations go, Coherus Oncology's Leases spiked by 73.13% in 2020, and later tumbled by 30.55% in 2022.
- Over the past 5 years, Coherus Oncology's Leases (Quarterly) stood at $10.0 million in 2020, then fell by 17.71% to $8.2 million in 2021, then slumped by 30.55% to $5.7 million in 2022, then climbed by 3.90% to $5.9 million in 2023, then dropped by 23.58% to $4.5 million in 2024.
- Its Leases stands at $4.5 million for Q4 2024, versus $5.9 million for Q4 2023 and $5.7 million for Q4 2022.